Sponsor hub
Amgen clinical trial failures
Review 104 stopped clinical trials from Amgen, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 15 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 57
- OTHER/UNKNOWN
- 32
- EFFICACY/FUTILITY
- 9
- SAFETY
- 6
Notable sponsors
- Amgen
- 104
Related phases
- Phase I
- 45
- Phase II
- 32
- Phase III
- 21
- Phase IV
- 5
- Early Phase I
- 1
Crawlable stopped-trial records
Open ExploreShowing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase I Solid Tumors trial by Amgen. Stop reason: OPERATIONAL.
Sponsor Decision
Phase II Discoid Lupus Erythematosus trial by Amgen. Stop reason: OPERATIONAL.
Sponsor business decision, not related to safety concerns.
Phase II Sjogren's Syndrome trial by Amgen. Stop reason: EFFICACY/FUTILITY.
The study was terminated by sponsor due to meeting pre-defined criteria for futility.
Phase I Healthy Volunteers trial by Amgen. Stop reason: OPERATIONAL.
Business Decision
Phase II Diffuse Cutaneous Systemic Sclerosis trial by Amgen. Stop reason: EFFICACY/FUTILITY.
The study was terminated due to meeting pre-defined criteria for futility.
Phase II Ulcerative Colitis trial by Amgen. Stop reason: EFFICACY/FUTILITY.
The study was terminated due to meeting a prespecified futility rule and not related to any safety concerns.
Phase II Diffuse Cutaneous Systemic Sclerosis trial by Amgen. Stop reason: OTHER/UNKNOWN.
The study was not stopped due to safety reasons
Phase II Idiopathic Pulmonary Fibrosis trial by Amgen. Stop reason: OTHER/UNKNOWN.
The trial was terminated due to not meeting primary or key secondary endpoints.
Phase I Metastatic Castration-resistant Prostate Cancer trial by Amgen. Stop reason: OPERATIONAL.
Sponsor Decision
Phase I Small Cell Lung Cancer trial by Amgen. Stop reason: OPERATIONAL.
Study on enrollment hold, may potentially resume. No active subjects on trial.
Phase II Ulcerative Colitis trial by Amgen. Stop reason: EFFICACY/FUTILITY.
The parent study 20170104 was terminated due to the study meeting a prespecified futility rule. Consequently, this study was terminated.
Phase I MUC17-positive Solid Tumors trial by Amgen. Stop reason: OPERATIONAL.
Business decision
Phase I Relapsed/Refractory Multiple Myeloma trial by Amgen. Stop reason: OPERATIONAL.
business decision, not safety reasons.
Phase I Non-squamous Non-small Cell Lung Cancer trial by Amgen. Stop reason: OPERATIONAL.
Sponsor strategic decision
Phase I Metastatic Castration-resistant Prostate Cancer trial by Amgen. Stop reason: OPERATIONAL.
Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not related to safety.
Phase I Relapsed and/or Refractory Multiple Myeloma trial by Amgen. Stop reason: OPERATIONAL.
Amgen re-evaluated the portfolio and decided to discontinue clinical development activities for AMG 420.
Phase I Higher Risk Myelodysplastic Syndrome trial by Amgen. Stop reason: OPERATIONAL.
Sponsor decision, unrelated to safety
Phase I Relapsed or Refractory Multiple Myeloma trial by Amgen. Stop reason: OPERATIONAL.
sponsor decision, unrelated to safety
Phase I Metastatic Castration-resistant Prostate Cancer trial by Amgen. Stop reason: OPERATIONAL.
Sponsor strategic decision
Phase IV B-precursor Acute Lymphoblastic Leukemia trial by Amgen. Stop reason: OPERATIONAL.
The decision to terminate is not based on safety or efficacy but due to slow enrollment impacting the ability to complete the study as planned.
Phase I Squamous-Cell Non-Small-Cell Lung Cancer trial by Amgen. Stop reason: OPERATIONAL.
Business decision not due to safety concerns
Phase II Lupus Nephritis trial by Amgen. Stop reason: OPERATIONAL.
Sponsor Decision
Phase II Focal Segmental Glomerulosclerosis trial by Amgen. Stop reason: OTHER/UNKNOWN.
Program not advancing
Phase II Mitochondrial Diseases trial by Amgen. Stop reason: OPERATIONAL.
Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001.
Phase II Hepatic Encephalopathy trial by Amgen. Stop reason: OPERATIONAL.
Study was terminated due to lack of enrollment and business decisions.
Phase I Safety Issues trial by Amgen. Stop reason: OTHER/UNKNOWN.
Study terminated due to tolerability issues.
Phase I Glioblastoma or Malignant Glioma trial by Amgen. Stop reason: OPERATIONAL.
Amgen business decision
Phase I Relapsed/Refractory Acute Myeloid Leukemia (AML) trial by Amgen. Stop reason: OPERATIONAL.
Premature discontinuation of study, a strategic decision.
Phase I Obesity trial by Amgen. Stop reason: OTHER/UNKNOWN.
Amgen determined the totality of the data does not support continuation of AMG 171 development program for treatment of Obesity. No safety concerns identified.
Phase II Systemic Lupus Erythematosus trial by Amgen. Stop reason: OPERATIONAL.
Sponsor Decision
Phase I Relapsed/Refractory AML trial by Amgen. Stop reason: OPERATIONAL.
Amgen strategic business decision to cancel following portfolio review, re-prioritization.
Phase I Non-small Cell Lung Cancer trial by Amgen. Stop reason: OPERATIONAL.
Amgen made a business decision to discontinue AMG 160 20180273
Phase I Diffuse Cutaneous Systemic Sclerosis trial by Amgen. Stop reason: OPERATIONAL.
Poor enrollment
Phase II Active Systemic Lupus Erythematosus trial by Amgen. Stop reason: EFFICACY/FUTILITY.
The trial was terminated prematurely as it met pre-defined criteria for futility at IA3.
Phase II Highly Sensitized Patients on Waiting List for Kidney Transplantation trial by Amgen. Stop reason: OPERATIONAL.
Stopped due to no enrollment
Phase III Dyslipidemia trial by Amgen. Stop reason: OPERATIONAL.
Amgen business decision to close study early
Phase I Healthy Participants trial by Amgen. Stop reason: OTHER/UNKNOWN.
FDA and EMA agreed existing data are appropriate for approval and no further BE studies are required.
Phase I Diffuse Large B-cell Lymphoma(DLBCL) trial by Amgen. Stop reason: OPERATIONAL.
Amgen decided to discontinue study because of a business decision and not because of safety reasons
Phase I Relapsed or Refractory Acute Myeloid Leukemia trial by Amgen. Stop reason: OTHER/UNKNOWN.
Amgen Decision
Phase III Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia trial by Amgen. Stop reason: SAFETY.
No stop-reason text available in the compact dataset.
Phase I Gastric and Gastroesophageal Junction Adenocarcinoma trial by Amgen. Stop reason: OPERATIONAL.
Business Decision
Phase I Chronic Graft Versus Host Disease cGVHD trial by Amgen. Stop reason: OPERATIONAL.
Sponsor Decision
Phase II Severe Aplastic Anemia (SAA) trial by Amgen. Stop reason: OTHER/UNKNOWN.
Operational
Early Phase I Acute Myeloid Leukemia trial by Amgen. Stop reason: OTHER/UNKNOWN.
Priortization of other Programs
Phase III Metastatic Non-small Cell Lung Cancer (NSCLC) trial by Amgen. Stop reason: OPERATIONAL.
Sponsor decision to early terminate the study
Phase I Relapsed/Refractory Acute Myeloid Leukemia trial by Amgen. Stop reason: OTHER/UNKNOWN.
Following a recent cellular therapy strategy assessment, Amgen has decided to cancel study 20180091.
Phase I Multiple Myeloma trial by Amgen. Stop reason: OPERATIONAL.
Strategic decisions
Phase III Primary Hypercholesterolemia trial by Amgen. Stop reason: OTHER/UNKNOWN.
Prematurely Discontinued Amgen decision
Phase III Osteogenesis Imperfecta trial by Amgen. Stop reason: SAFETY.
The study was stopped earlier than planned due to safety concerns about high levels of calcium in the blood of the participants
Phase III Osteogenesis Imperfecta (OI) trial by Amgen. Stop reason: SAFETY.
The study was stopped earlier than planned due to safety concerns about high levels of calcium in the blood of the participants
Phase III Non-Small Cell Lung Cancer trial by Amgen. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Anemia trial by Amgen. Stop reason: OPERATIONAL.
FDA and EMA agreed that the information that had been submitted to date was acceptable to meet the requirements of the post-marketing commitment.
Phase I Multiple Myeloma trial by Amgen. Stop reason: OPERATIONAL.
A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ003 was halted during dose-escalation.
Phase III Melanoma trial by Amgen. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Multiple Myeloma trial by Amgen. Stop reason: OPERATIONAL.
A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in 2011-001 was halted.
Phase I Advanced Malignancy trial by Amgen. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Relapsed/Refractory Multiple Myeloma trial by Amgen. Stop reason: OPERATIONAL.
Amgen Decision to stop development of AMG 701 SC, not for safety reasons but for business reasons.
Phase II Asthma trial by Amgen. Stop reason: EFFICACY/FUTILITY.
Study terminated early due to lack of efficacy observed following interim analysis in Q2 2015. Study Closed once all sites were closed in eClinical
Phase I Heart Failure trial by Amgen. Stop reason: OTHER/UNKNOWN.
Terminated (Decision by the Sponsor. The study was not terminated due to a safety reason.)
Phase IV Migraine trial by Amgen. Stop reason: OPERATIONAL.
Terminated \[Study would not complete enrollment target until 2026 with results available in 2027. The information will not be useful at that time.\]
Phase II Atopic Dermatitis trial by Amgen. Stop reason: OTHER/UNKNOWN.
Tezepelumab as a monotherapy in atopic dermatitis did not reach the targeted efficacy level pre-established for this patient population.
Phase II Rheumatoid Arthritis trial by Amgen. Stop reason: EFFICACY/FUTILITY.
Lack of efficacy for Brodalumab in Rheumatoid Arthritis (RA)
Phase II Crohn's Disease trial by Amgen. Stop reason: OTHER/UNKNOWN.
The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups
Phase II Crohn's Disease trial by Amgen. Stop reason: OTHER/UNKNOWN.
The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups.
Phase III Breast Cancer trial by Amgen. Stop reason: OTHER/UNKNOWN.
Terminated: Amgen decision following Primary Analysis. Not due to safety reason
Phase I Rheumatoid Arthritis RA trial by Amgen. Stop reason: OPERATIONAL.
Amgen made a business decision not to proceed with Phase 2.
Phase I Multiple Myeloma trial by Amgen. Stop reason: OPERATIONAL.
A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ007 was halted during dose-expansion.
Phase I GI Adenocarcinoma trial by Amgen. Stop reason: OPERATIONAL.
The study was terminated because of immunogenicity and business decision.
Phase I Advanced Non-Central Nervous System (CNS) Malignancies trial by Amgen. Stop reason: OPERATIONAL.
Why study stopped revised to "A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ009 was halted
Phase II Relapsed or Refractory Multiple Myeloma trial by Amgen. Stop reason: OPERATIONAL.
Sponsor Decision
Phase II High-risk Diffuse Large B-cell Lymphoma trial by Amgen. Stop reason: OPERATIONAL.
Early Closure due to rare patient population
Phase I Multiple Myeloma trial by Amgen. Stop reason: OPERATIONAL.
Enrollment halted during phase 2 to reformulate the investigational product
Phase III Chronic Kidney Disease trial by Amgen. Stop reason: SAFETY.
Study was put on clinical hold on 30 Jan 2013 following a subject fatality. Study was never restarted and was closed.
Phase III Chronic Kidney Disease, Secondary Hyperparathyroidism trial by Amgen. Stop reason: OTHER/UNKNOWN.
Amgen decided to terminate the study early to be able to meet US regulatory timelines fo filing. Subjects in treatment were rolled over to the 20140159 study.
Phase II Chronic Kidney Disease trial by Amgen. Stop reason: OPERATIONAL.
Amgen decided to terminate the study early to be able to meet US regulatory timelines fo filing. Subjects in treatment were rolled over to the 20140159 study.
Phase II Rheumatoid Arthritis trial by Amgen. Stop reason: EFFICACY/FUTILITY.
Study is terminated due to lack of efficacy
Phase III Juvenile Rheumatoid Arthritis trial by Amgen. Stop reason: OPERATIONAL.
the study was terminated because of slow enrollment
Phase III Juvenile Rheumatoid Arthritis trial by Amgen. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Heart Transplantation, Elevated Resting Heart Rate trial by Amgen. Stop reason: OPERATIONAL.
Sponsor decision
Phase II Age-associated Muscle Loss trial by Amgen. Stop reason: OTHER/UNKNOWN.
Amgen has chosen at this time not to continue with AMG 745 study 20080733
Phase I Oncology trial by Amgen. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Diabetes Mellitus trial by Amgen. Stop reason: OTHER/UNKNOWN.
Program Development discontinued
Phase IV Moderate to Severe Rheumatoid Arthritis trial by Amgen. Stop reason: OPERATIONAL.
Business decision due to slow enrollment
Phase III Chemotherapy-induced Thrombocytopenia trial by Amgen. Stop reason: OPERATIONAL.
Study was not feasible
Phase II Advanced Non-squamous NSCLC trial by Amgen. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase IV Psoriasis trial by Amgen. Stop reason: OPERATIONAL.
Business decision due to slow enrollment
Phase III Fallopian Tube Cancer trial by Amgen. Stop reason: OTHER/UNKNOWN.
Closure of long term follow up (LTFU) and study earlier than previously outlined in the protocol as no beneficial information gained from continuing LTFU.
Phase II Stomach Neoplasms trial by Amgen. Stop reason: OTHER/UNKNOWN.
Amgen decision following interim review of efficacy and safety data from the AMG 337 program.
Phase I Postmenopausal trial by Amgen. Stop reason: OPERATIONAL.
Lack of enrollment.
Phase I Advanced Hepatocellular Carcinoma trial by Amgen. Stop reason: OPERATIONAL.
Study stopped due to administrative reasons
Phase III Fallopian Tube Cancer trial by Amgen. Stop reason: OPERATIONAL.
Amgen Administrative Decision - termination of LTFU
Phase I Anemia trial by Amgen. Stop reason: OPERATIONAL.
Difficulty in recruitment. PDCO in the Day 30 summary report agrred to remove the PK study in children \<1 year of age.
Phase I Rheumatoid Arthritis trial by Amgen. Stop reason: OTHER/UNKNOWN.
Study has stopped due to a decision by Amgen to terminate the program
Phase III Gastric Cancer trial by Amgen. Stop reason: SAFETY.
All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622.
Phase III Gastric Cancer trial by Amgen. Stop reason: SAFETY.
All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622.
Phase I Diabetes Mellitus trial by Amgen. Stop reason: OPERATIONAL.
This study was terminated on August 29th, 2014 due to a business decision by the Sponsor. The study was not terminated due to a safety reason.
Phase II Breast Neoplasms trial by Amgen. Stop reason: OPERATIONAL.
Sponsor decision to close study
Phase II Solid Tumors trial by Amgen. Stop reason: OTHER/UNKNOWN.
Amgen decision
Phase III Non-Small Cell Lung Cancer trial by Amgen. Stop reason: EFFICACY/FUTILITY.
Amgen discontinued the development of AMG706 because 20050201 did not meet its primary objective.
Phase II Schizophrenia trial by Amgen. Stop reason: OTHER/UNKNOWN.
Toxic Epidermal Necrolysis